Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay

Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay

Undetectable minimal residual disease (MRD) in Chronic Lymphocytic Leukemia (CLL) has a favorable prognostic outcome compared with MRD that can be detected. This study investigated a flow cytometric assay (CD160-ROR1FCA) targeting the tumor-specific antigens CD160 and receptor tyrosine kinase-like o...

Full description

Bibliographic Details
Main Authors: Timothy W. Farren, Kaushik S. Sadanand, Samir G. Agrawal
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Oncology
Subjects:
CD160
ROR-1
minimal/measurable residual disease
chronic lymphocytic leukemia
monoclonal B-cell lymphocytosis
flow cytometry
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.597730/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.597730/full

Similar Items